Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma

World Journal of Gastroenterology

Volumn 19, Issue 12, 2013, Pages 1912-1918

  Lu, Xiao Xia ^a   Chen, Yi Tian ^a   Feng, Bing ^a   Mao, Xiao Bei ^a   Yu, Bo ^b   Chu, Xiao Yuan ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

Author keywords

CD73; Gastric carcinoma; Hypoxia inducible factor 1a; Immunohistochemistry; Prognosis

Indexed keywords

5' NUCLEOTIDASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ADULT; ARTICLE; CANCER INVASION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; STOMACH CARCINOMA;

EID: 84875590401     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i12.1912     Document Type: Article

References (38)

1. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003; 56: 1-9 [PMID: 12589864 DOI: 10.1016/S0895-4356(02)00534-6]
2. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005; 6: 331-337 [PMID: 15785758 DOI: 10.1038/ni1179]
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108 [PMID: 15761078 DOI: 10.3322/canjclin.55.2.74]
4. Krejs GJ. Gastric cancer: epidemiology and risk factors. Dig Dis 2010; 28: 600-603 [PMID: 21088409 DOI: 10.1159/000320277]
5. Resta R, Yamashita Y, Thompson LF. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev 1998; 161: 95-109 [PMID: 9553767 DOI: 10.1111/j.1600-065X.1998. tb01574.x]
6. Haskó G, Pacher P. A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol 2008; 83: 447-455 [PMID: 18160539 DOI: 10.1189/jlb.0607359]
7. Colgan SP, Eltzschig HK, Eckle T, Thompson LF. Physiological roles for ecto-5'-nucleotidase (CD73). Purinergic Signal 2006; 2: 351-360 [PMID: 18404475 DOI: 10.1007/ s11302-005-5302-5]
8. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 2001; 41: 775-787 [PMID: 11264476 DOI: 10.1146/annurev.pharmtox.41.1.775]
9. Wu XR, He XS, Chen YF, Yuan RX, Zeng Y, Lian L, Zou YF, Lan N, Wu XJ, Lan P. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J Surg Oncol 2012; 106: 130-137 [PMID: 22287455 DOI: 10.1002/ jso.23056]
10. Häusler SF, Montalbán del Barrio I, Strohschein J, Anoop Chandran P, Engel JB, Hönig A, Ossadnik M, Horn E, Fischer B, Krockenberger M, Heuer S, Seida AA, Junker M, Kneitz H, Kloor D, Klotz KN, Dietl J, Wischhusen J. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol Immunother 2011; 60: 1405-1418 [PMID: 21638125 DOI: 10.1007/s00262-011-1040-4]
11. Kondo T, Nakazawa T, Murata SI, Katoh R. Expression of CD73 and its ecto-5'-nucleotidase activity are elevated in papillary thyroid carcinomas. Histopathology 2006; 48: 612-614 [PMID: 16623792 DOI: 10.1111/j.1365-2559.2005.02277.x]
12. Spychala J, Lazarowski E, Ostapkowicz A, Ayscue LH, Jin A, Mitchell BS. Role of estrogen receptor in the regulation of ecto-5'-nucleotidase and adenosine in breast cancer. Clin Cancer Res 2004; 10: 708-717 [PMID: 14760094 DOI: 10.1158/1078-0432.ccr-0811-03]
13. Gocmen E, Tez M, Ozturk S, Koc M, Demirci S. Activities of adenosine deaminase and 5'-nucleotidase in cancereous and non-cancereous human gastric tissues. Bratisl Lek Listy 2009; 110: 416-418 [PMID: 19711828]
14. Mizokami K, Kakeji Y, Oda S, Irie K, Yonemura T, Konishi F, Maehara Y. Clinicopathologic significance of hypoxiainducible factor 1alpha overexpression in gastric carcinomas. J Surg Oncol 2006; 94: 149-154 [PMID: 16847924 DOI: 10.1002/jso.20568]
15. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008; 15: 678-685 [PMID: 18259193 DOI: 10.1038/cdd.2008.21]
16. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 2000; 88: 2606-2618 [PMID: 10861440]
17. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001; 93: 309-314 [PMID: 11181778 DOI: 10.1093/jnci/93.4.309]
18. Kuwai T, Kitadai Y, Tanaka S, Onogawa S, Matsutani N, Kaio E, Ito M, Chayama K. Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer 2003; 105: 176-181 [PMID: 12673675 DOI: 10.1002/ijc.11068]
19. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, Hansen KR, Thompson LF, Colgan SP. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 2002; 110: 993-1002 [PMID: 12370277 DOI: 10.1172/jci200215337]
20. Wang JH, Huang WS, Hu CR, Guan XX, Zhou HB, Chen LB. Relationship between RGS5 expression and differentiation and angiogenesis of gastric carcinoma. World J Gastroenterol 2010; 16: 5642-5646 [PMID: 21105200 DOI: 10.3748/wjg.v16. i44.5642]
21. Zhou J, Zhang L, Gu Y, Li K, Nie Y, Fan D, Feng Y. Dynamic expression of CEACAM7 in precursor lesions of gastric carcinoma and its prognostic value in combination with CEA. World J Surg Oncol 2011; 9: 172 [PMID: 22195770 DOI: 17210.1186/1477-7819-9-172]
22. Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, Shin T, Curiel TJ, Zhang B. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res 2010; 70: 2245-2255 [PMID: 20179192 DOI: 10.1158/0008-5472.can-09-3109]
23. Hoskin DW, Mader JS, Furlong SJ, Conrad DM, Blay J. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol 2008; 32: 527-535 [PMID: 18292929]
24. Wang L, Zhou X, Zhou T, Ma D, Chen S, Zhi X, Yin L, Shao Z, Ou Z, Zhou P. Ecto-5'-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol 2008; 134: 365-372 [PMID: 17671792 DOI: 10.1007/s00432-007-0292-z]
25. Zhi X, Wang Y, Zhou X, Yu J, Jian R, Tang S, Yin L, Zhou P. RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells. Cancer Sci 2010; 101: 2561-2569 [PMID: 20874842 DOI: 10.1111/ j.1349-7006.2010.01733.x]
26. Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, Dwyer KM, Smyth MJ. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci USA 2010; 107: 1547-1552 [PMID: 20080644 DOI: 10.1073/pnas.0908801107]
27. Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, Smyth MJ. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 2011; 71: 2892-2900 [PMID: 21292811 DOI: 10.1158/0008-5472.can-10-4246]
28. Wang L, Fan J, Thompson LF, Zhang Y, Shin T, Curiel TJ, Zhang B. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest 2011; 121: 2371-2382 [PMID: 21537079 DOI: 10.1172/ jci45559]
29. Yegutkin GG, Marttila-Ichihara F, Karikoski M, Niemelä J, Laurila JP, Elima K, Jalkanen S, Salmi M. Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur J Immunol 2011; 41: 1231-1241 [PMID: 21469131 DOI: 10.1002/eji.201041292]
30. Li X, Zhou T, Zhi X, Zhao F, Yin L, Zhou P. Effect of hypoxia/ reoxygenation on CD73 (ecto-5'-nucleotidase) in mouse microvessel endothelial cell lines. Microvasc Res 2006; 72: 48-53 [PMID: 16828810 DOI: 10.1016/j.mvr.2006.04.005]
31. Bunn HF, Poyton RO. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 1996; 76: 839-885 [PMID: 8757790]
32. Saramäki OR, Savinainen KJ, Nupponen NN, Bratt O, Visakorpi T. Amplification of hypoxia-inducible factor 1alpha gene in prostate cancer. Cancer Genet Cytogenet 2001; 128: 31-34 [PMID: 11454426 DOI: 10.1016/s0165-4608(01)00396-x]
33. Theodoropoulos VE, Lazaris ACH, Sofras F, Gerzelis I, Tsoukala V, Ghikonti I, Manikas K, Kastriotis I. Hypoxiainducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 2004; 46: 200-208 [PMID: 15245814 DOI: 10.1016/ j.eururo.2004.04.008]
34. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001; 7: 1661-1668 [PMID: 11410504]
35. Büchler P, Reber HA, Büchler M, Shrinkante S, Büchler MW, Friess H, Semenza GL, Hines OJ. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas 2003; 26: 56-64 [PMID: 12499918 DOI: 10.1097/00006676-200301000-00010]
36. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, Semenza GL. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61: 2911-2916 [PMID: 11306467]
37. Lu XG, Xing CG, Feng YZ, Chen J, Deng C. Clinical significance of immunohistochemical expression of hypoxiainducible factor-1alpha as a prognostic marker in rectal adenocarcinoma. Clin Colorectal Cancer 2006; 5: 350-353 [PMID: 16512994 DOI: 10.3816/CCC.2006.n.005]
38. Dellas K, Bache M, Pigorsch SU, Taubert H, Kappler M, Holzapfel D, Zorn E, Holzhausen HJ, Haensgen G. Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervical cancer. Strahlenther Onkol 2008; 184: 169-174 [PMID: 18330514 DOI: 10.1007/s00066-008-1764-z]